Login to Your Account

Telavancin OK'd After Long, Painful Road to Approval

By Donna Young

Tuesday, September 15, 2009
Nearly three years after Theravance Inc. and Astellas Pharma US Inc. filed their application for telavancin, a once-daily injectable antibiotic to treat adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), the FDA finally granted approval of the long-embattled drug. (BioWorld World)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription